HCC Patient Preferences in Japan

Status Completed

Clinical Trial Summary

This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will include sorafenib (which will be described as 'oral anti-cancer therapy'), repeated transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). Please note that all interventions that patients may have received before completing this online survey were given regardless of their participation in this survey. Questions also include asking patients to rank various treatment characteristics (e.g., mechanism of action, risk of adverse effects, etc.) relative to each other. The ultimate goal is to better understand patient perceptions of these treatments and to provide evidence to help in patients' and physicians' treatment decision-making in HCC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02616692
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase	N/A
Start date	May 9, 2016
Completion date	October 7, 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03971201` - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion	Phase 2
Recruiting	`NCT04484636` - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	N/A
Recruiting	`NCT05489250` - The PLATON Network
Completed	`NCT01967823` - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer	Phase 2
Terminated	`NCT00878215` - Clinical Application of Image-Guided Liver Surgery	Phase 2
Completed	`NCT04212286` - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC	N/A
Recruiting	`NCT05992220` - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion	Phase 2
Completed	`NCT02073435` - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting	`NCT01522937` - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer	Phase 2
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04166240` - Measuring and Improving the Safety of Test Result Follow-Up	N/A
Withdrawn	`NCT02288507` - Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer	Phase 1
Terminated	`NCT03026803` - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer	Phase 2
Active, not recruiting	`NCT04682847` - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Active, not recruiting	`NCT05100082` - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting	`NCT03195699` - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	Phase 1
Active, not recruiting	`NCT03132792` - AFPᶜ³³²T in Advanced HCC	Phase 1
Recruiting	`NCT01849588` - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C	Phase 4
Suspended	`NCT00909558` - Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer	Phase 1
Completed	`NCT00997022` - Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients	Phase 1